New Generic Drug House Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 0.97 Cr
as on 28-06-2024
- Company Age 41 Year, 4 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 6.85 Cr
as on 28-06-2024
- Revenue -50.00%
(FY 2018)
- Profit 97.04%
(FY 2018)
- Ebitda 74.38%
(FY 2018)
- Net Worth -0.00%
(FY 2018)
- Total Assets 0.12%
(FY 2018)
About New Generic Drug House
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.97 Cr.
The company has closed loans amounting to ₹6.85 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jasumati Vyas and Dhirajlal Patel serve as directors at the Company.
- CIN/LLPIN
U24230GJ1983PTC006156
- Company No.
006156
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 1983
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Valsad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at New Generic Drug House?
Board Members(2)
Financial Performance and Corporate Structure Insights of New Generic Drug House.
New Generic Drug House Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 50% decrease. The company also saw a substantial improvement in profitability, with a 97.04% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of New Generic Drug House?
In 2018, New Generic Drug House had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Jankalyan Sehkari Bank Ltd Creation Date: 29 Mar 2004 | ₹3.50 M | Satisfied |
Jankalyan Sehkari Bank Ltd Creation Date: 23 Jul 2003 | ₹7.50 M | Satisfied |
Jankalyan Sehkari Bank Ltd Creation Date: 16 Jan 2002 | ₹2.00 Cr | Satisfied |
How Many Employees Work at New Generic Drug House?
Unlock and access historical data on people associated with New Generic Drug House, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of New Generic Drug House, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped New Generic Drug House's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
